国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2014年
9期
662-665
,共4页
乳腺肿瘤%抗肿瘤药%靶向治疗
乳腺腫瘤%抗腫瘤藥%靶嚮治療
유선종류%항종류약%파향치료
Breast neoplasms%Antineoplastic agents%Molecular targeted therapy
由于不能从传统的内分泌治疗及针对人表皮生长因子受体2（HER-2）的靶向治疗中获益，除手术治疗外，目前化疗是三阴性乳腺癌（TNBC）主要的全身治疗手段。由于传统化疗疗效不理想， TNBC的靶向治疗正成为研究热点。已有大量临床试验发现靶向聚二磷酸腺苷核糖聚合酶1（PARP-1）抑制剂、血管内皮生长因子（VEGF）抑制剂、表皮生长因子受体（EGFR）抑制剂等能使TNBC患者不同程度获益。
由于不能從傳統的內分泌治療及針對人錶皮生長因子受體2（HER-2）的靶嚮治療中穫益，除手術治療外，目前化療是三陰性乳腺癌（TNBC）主要的全身治療手段。由于傳統化療療效不理想， TNBC的靶嚮治療正成為研究熱點。已有大量臨床試驗髮現靶嚮聚二燐痠腺苷覈糖聚閤酶1（PARP-1）抑製劑、血管內皮生長因子（VEGF）抑製劑、錶皮生長因子受體（EGFR）抑製劑等能使TNBC患者不同程度穫益。
유우불능종전통적내분비치료급침대인표피생장인자수체2（HER-2）적파향치료중획익，제수술치료외，목전화료시삼음성유선암（TNBC）주요적전신치료수단。유우전통화료료효불이상， TNBC적파향치료정성위연구열점。이유대량림상시험발현파향취이린산선감핵당취합매1（PARP-1）억제제、혈관내피생장인자（VEGF）억제제、표피생장인자수체（EGFR）억제제등능사TNBC환자불동정도획익。
Treatment options are limited for triple negative breast cancer (TNBC)since endocrinother-apy and targeted therapy that aims directly at human epidermal growth factor receptor-2 (HER-2)are ineffec-tive.As such,in addition to surgical treatment,the mainstay of treatment of TNBC is systemic cytotoxic chemo-therapy.The targeted therapy of TNBC is becoming a research hotspot because of traditional chemotherapy cura-tive effect is not good enough.A large number of clinical trials have found that patients with TNBC can get ben-efits from targeted molecular strategies including poly-adenosine diphosphate glucose pyrophospheralase-ribose polymerase-1 (PARP-1 )inhibitor and epidermal growth factor receptor (EGFR)inhibitor.
